Monitoring of l-arginine and endogenous dimethylarginines in survivor septic patients-a pilot study

Balázs Németh, István Kiss, Iván Péter, Zénó Ajtay, Ádám Németh, László Márk, Attila Csorba, Tamás Kszegi, Diána Mühl, Péter Kustán

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aim: Nitric oxide (NO) pathway plays a major role in the development and advancement of inflammation. We aimed to design a study and investigate its feasibility to show the changes of L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are important regulators of the NO pathway. Patients and Methods: Concentrations of L-arginine, ADMA and SDMA were measured by liquid chromatographytandem mass spectrometry. Seventeen septic survival patients were enrolled and blood samples were obtained on the first, third and fifth day after the diagnosis of sepsis. Sixteen nonseptic matched controls were recruited. Results: ADMA levels on admission correlated well with sequential organ failure assessment (SOFA) score. During the follow-up, Larginine/ ADMA ratio increased significantly from day 1 to day 3 (p=0.005), then decreased from day 3 to day 5 (p=0.023). Conclusion: This study design seems feasible to investigate changes of L-Arginine, ADMA and SDMA in sepsis survival patients.

Original languageEnglish
Pages (from-to)663-669
Number of pages7
JournalIn Vivo
Volume30
Issue number5
Publication statusPublished - Sep 1 2016

    Fingerprint

Keywords

  • Asymmetric dimethylarginine
  • L-arginine
  • Nitric oxide
  • Sepsis
  • Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Németh, B., Kiss, I., Péter, I., Ajtay, Z., Németh, Á., Márk, L., Csorba, A., Kszegi, T., Mühl, D., & Kustán, P. (2016). Monitoring of l-arginine and endogenous dimethylarginines in survivor septic patients-a pilot study. In Vivo, 30(5), 663-669.